webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

MC-Val-Cit-PAB-Retapamulin

  CAS No.: 1639793-15-9   Cat No.: BADC-00612 4.5  

MC-Val-Cit-PAB-retapamulin has a bioreversible linkage based on a quaternary ammonium for targeted delivery and it can improve pharmacokinetics and the therapeutic index. MC-Val-Cit-PAB-retapamulin is used for the antibody-drug conjugates (ADC) that are effective and stable in vitro and in vivo to treat various diseases or disorders.

MC-Val-Cit-PAB-Retapamulin

Structure of 1639793-15-9

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Cytotoxin with Linker
Molecular Formula
C58H86N7O10S
Molecular Weight
1073.41
Shipping
Room temperature

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
IUPAC Name
[(2R,3S,4S,6R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[[(1R,5S)-8-[[4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl]-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl]sulfanyl]acetate
Canonical SMILES
C[C@@H]1C23[C@](C(CC3)=O)([H])C([C@H](OC(CS[C@@H]4C[C@@H]5[N@+](CC6=CC=C(NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCCCCN7C(C=CC7=O)=O)=O)=O)=O)C=C6)(C)[C@@H](CC5)C4)=O)C[C@](C=C)(C)[C@H]1O)([C@H](C)CC2)C
InChI
InChI=1S/C58H85N7O10S/c1-9-56(6)32-45(57(7)36(4)24-26-58(37(5)52(56)71)27-25-44(66)51(57)58)75-49(70)34-76-42-30-40-20-21-41(31-42)65(40,8)33-38-16-18-39(19-17-38)61-53(72)43(14-13-28-60-55(59)74)62-54(73)50(35(2)3)63-46(67)15-11-10-12-29-64-47(68)22-23-48(64)69/h9,16-19,22-23,35-37,40-43,45,50-52,71H,1,10-15,20-21,24-34H2,2-8H3,(H5-,59,60,61,62,63,67,72,73,74)/p+1/t36-,37+,40-,41+,42?,43+,45-,50+,51+,52+,56-,57?,58?,65?/m1/s1
Shipping
Room temperature

MC-Val-Cit-PAB-Retapamulin is a drug conjugate that combines the antibiotic retapamulin, a potent inhibitor of bacterial protein synthesis, with a peptide linker (MC-Val-Cit-PAB) designed for targeted delivery. Retapamulin is effective against various Gram-positive bacteria, including drug-resistant strains, by binding to the bacterial ribosome and blocking protein elongation. The peptide linker in MC-Val-Cit-PAB-Retapamulin enables selective activation and release of retapamulin at specific target sites, improving its therapeutic efficacy while minimizing side effects associated with systemic drug exposure.

One primary application of MC-Val-Cit-PAB-Retapamulin is in the targeted treatment of bacterial infections, particularly those caused by multidrug-resistant (MDR) pathogens. The peptide linker is designed to be cleaved by enzymes or specific conditions present in the infected tissue, ensuring that retapamulin is released at the site of infection. By directing the drug precisely to the infected area, this approach can enhance the concentration of the antibiotic where it is needed most, reducing the risk of off-target effects and minimizing toxicity to healthy tissues. This makes it a promising candidate for addressing complex infections, including those caused by resistant bacterial strains.

MC-Val-Cit-PAB-Retapamulin also holds potential in the development of novel therapeutic strategies for treating chronic infections, such as those associated with biofilms. Biofilm-forming bacteria are notoriously difficult to treat with conventional antibiotics due to their resistance mechanisms and reduced drug penetration. The targeted release system in MC-Val-Cit-PAB-Retapamulin allows for more efficient delivery to biofilm-associated bacteria, where it can exert its antimicrobial effect directly on the bacterial cells. This targeted approach could lead to more effective treatment of chronic infections in hard-to-reach sites, improving outcomes in patients with persistent bacterial infections.

Additionally, MC-Val-Cit-PAB-Retapamulin can be utilized in the context of personalized medicine. The peptide linker in the conjugate can be tailored to target specific biomarkers or receptors present on the surface of bacterial cells or infected tissues. This level of specificity allows for more precise treatment, offering patients a more individualized approach to combating infections. By customizing the drug delivery system based on patient-specific factors, such as the type of infection or the bacterial strain involved, MC-Val-Cit-PAB-Retapamulin can improve therapeutic outcomes and reduce the risk of adverse effects.

Finally, MC-Val-Cit-PAB-Retapamulin can play a significant role in antibiotic stewardship programs by enabling more effective and targeted antibiotic use. By focusing antibiotic therapy directly on the infection site, the conjugate helps to minimize the overuse of broad-spectrum antibiotics, which is a leading cause of antibiotic resistance. This targeted approach could help preserve the effectiveness of existing antibiotics like retapamulin and reduce the overall burden of resistance, contributing to the global efforts to combat antibiotic resistance and promote more sustainable antibiotic use.

1.Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates
Staben LR, et al.
The reversible attachment of a small-molecule drug to a carrier for targeted delivery can improve pharmacokinetics and the therapeutic index. Previous studies have reported the delivery of molecules that contain primary and secondary amines via an amide or carbamate bond; however, the ability to employ tertiary-amine-containing bioactive molecules has been elusive. Here we describe a bioreversible linkage based on a quaternary ammonium that can be used to connect a broad array of tertiary and heteroaryl amines to a carrier protein. Using a concise, protecting-group-free synthesis we demonstrate the chemoselective modification of 12 complex molecules that contain a range of reactive functional groups. We also show the utility of this connection with both protease-cleavable and reductively cleavable antibody-drug conjugates that were effective and stable in vitro and in vivo. Studies with a tertiary-amine-containing antibiotic show that the resulting antibody-antibiotic conjugate provided appropriate stability and release characteristics and led to an unexpected improvement in activity over the conjugates previously connected via a carbamate.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Payload Development Biological Payload ADC Linker–Payload Conjugation ADC Linker Development Chemical Payload Enzyme Cleavable Linker Cathepsin B Cleavable Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Maytansine and Its Analogues Linkers - A Crucial Factor in Antibody–Drug Conjugates Cytotoxic Agents Used in Antibody–Drug Conjugates Exatecan Mesylate in ADCs: A New Topo I Inhibitor What is Calicheamicin? What is Monomethyl Auristatin E (MMAE)? What is Monomethyl Auristatin F (MMAF)? What is Pyrrolobenzodiazepine (PBD)? Antiviral Potential of Thapsigargin in COVID-19 Research In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: PEG4-aminooxy-MMAF | DBA-DM4 | MAC glucuronide linker | SPDB | SPDPH | Doxorubicin-SMCC | m-PEG1-NHS ester | SG3199 | Azido-PEG3-maleimide | sulfo-LC-SPDP | MC-Val-Cit-PAB-Retapamulin
Send Inquiry
Verification code
Inquiry Basket